Aptargroup Beats Q2 EPS Estimate
Aptargroup reports Q2 adjusted EPS of $1.42
ATR - Aptargroup Q2 -Adj.
EPS $1.42 vs est $1.35 -Sales $1.027B vs est $1.008B - Sees Q3 Adj EPS $1.45-$1.53 vs $1.46 Est - "We were pleased to deliver revenue growth across all three segments during the quarter.
Aptar Pharma continued to lead the way, driven by double-digit growth in consumer Healthcare, and high single-digit growth in injectables and prescription, excluding emergency Medicine.
In Beauty, strong demand in Prestige fragrance solutions supported growth, while Closures benefited from continued strength in Beverage dispensing.
While margins are currently impacted by product mix and operational factors, we remain confident in the company’s long-term margin structure, supported by strong demand trends across key Pharma franchises, continued momentum in Closures, and the actions underway to enhance operational performance.
As I conclude my tenure as CEO at Aptar, I am pleased to hand the company over following a quarter that reflects solid performance, a strong balance sheet and an improving growth trajectory in the outlook.
These results demonstrate the dedication of our teams, the strength of our innovation-led portfolio and our ability to create value for customers across attractive end markets," said Stephan B.
Tanda, Aptar President and CEO.